IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$25.74 USD
-0.48 (-1.83%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $25.77 +0.03 (0.12%) 6:38 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
IDEAYA Biosciences, Inc.'s return on equity, or ROE, is -31.43% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that IDYA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
IDYA 25.74 -0.48(-1.83%)
Will IDYA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IDYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IDYA
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
IDYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know
Other News for IDYA
Is IDYA showing upside potential? Crossed Above 20 Day Moving Average shows up after rallying 7.28%
Guggenheim Initiates Coverage on IDEAYA Biosciences (IDYA) with a Buy Rating | IDYA Stock News
Is IDYA heading for a slide? 20 Day Moving Average Resistance shows up after sliding 1.13%
Immunocore initiated at neutral at Guggenheim as Kimmtrak priced into shares
20 Day Moving Average Resistance appears for IDYA after 0.77% move